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The search for genetic variants associated with ovarian cancer risk has focused on pathways including sex steroid hormones,
DNA repair, and cell cycle control. The Ovarian Cancer Association Consortium (OCAC) identified 10 single-nucleotide
polymorphisms (SNPs) in genes in these pathways, which had been genotyped by Consortium members and a pooled analysis
of these data was conducted. Three of the 10 SNPs showed evidence of an association with ovarian cancer at Pp0.10 in
a log-additive model: rs2740574 in CYP3A4 (P¼0.011), rs1805386 in LIG4 (P¼0.007), and rs3218536 in XRCC2 (P¼0.095).
Additional genotyping in other OCAC studies was undertaken and only the variant in CYP3A4, rs2740574, continued to
show an association in the replication data among homozygous carriers: ORhomozygous(hom)¼2.50 (95% CI 0.54-11.57, P¼0.24)
with 1406 cases and 2827 controls. Overall, in the combined data the odds ratio was 2.81 among carriers of two copies of
the minor allele (95% CI 1.20–6.56, P¼0.017, phet across studies¼0.42) with 1969 cases and 3491 controls. There was no
association among heterozygous carriers. CYP3A4 encodes a key enzyme in oestrogen metabolism and our finding between
rs2740574 and risk of ovarian cancer suggests that this pathway may be involved in ovarian carcinogenesis. Additional follow-up is
warranted.
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sOvarian cancer is the second most common gynaecologic cancer
and the leading cause of gynaecologic cancer death; it is estimated
that there were B22000 new diagnoses of ovarian cancer and
B15000 deaths from the disease in the United States in 2007. In
some families Mendelian inheritance of ovarian cancer is observed
and high penetrance alleles have been identified in several genes
including BRCA1, BRCA2, and DNA mismatch repair genes.
However, disease-associated alleles of these genes account for less
than 40% of the inherited variance in disease risk (Antoniou and
Easton, 2006). Population-based case–control studies have
described a two to three-fold increased risk in first-degree relatives
of ovarian cancer patients (Godard et al, 1998; Stratton et al, 1998)
and heritability is estimated to be approximately 22% (Lichten-
stein et al, 2000). Ovarian cancer is probably a complex genetic
disease with locus and allelic heterogeneity (Lander and Schork,
1994), and such complex traits are likely to be because of
combinations of common, less penetrant alleles (Risch and
Merikangas, 1996). However, the common alleles that might be
responsible for susceptibility to ovarian cancer remain poorly
understood.
The most powerful approach for identifying common, low-
penetrance disease susceptibility alleles is the genetic association
study. Until recently, most association studies have focused on the
candidate gene approach in which common genetic variation in
biologically relevant pathways is tested for association with
disease. However, this approach has had limited success, and few
initial findings of positive associations have been replicated in
subsequent studies (Ioannidis et al, 2001; Lohmueller et al, 2003).
One of the main reasons for these failures has been the limited
power of small studies to detect associations at highly stringent
levels of statistical significance. This is a particular problem in
ovarian cancer where the largest individual studies have fewer than
2000 cases.
The Ovarian Cancer Association Consortium (OCAC) was
formed in 2005 to provide a forum for testing candidate ovarian
cancer susceptibility alleles in multiple studies with a large
combined sample size (Gayther et al, 2007; Pearce et al, 2008;
Ramus et al, 2008). Prior to the formation of the OCAC most
groups had been carrying out candidate gene studies autono-
mously, although in many instances they had been studying the
same candidate single nucleotide polymorphisms (SNPs) and
genes. The purpose of the current study was to evaluate the
evidence for association in SNPs, which had already been
genotyped by multiple studies by combining the existing data.
Where evidence for association emerged from these data, the
associated SNPs were then genotyped in additional OCAC studies
for replication.
MATERIALS AND METHODS
Study populations
The Ovarian Cancer Association Consortium is comprised of
ovarian cancer case–control and cohort studies conducted around
the world (Gayther et al, 2007; Pearce et al, 2008; Ramus et al,
2008). Included in this report are data from 16 OCAC studies. Ten
of these are from the USA: the Diseases of the Ovary and their
Evaluation (DOVE), the Genetic Epidemiology of Ovarian Cancer
Study (GEOCS; previously FROCS) (Auranen et al, 2005; Song
et al, 2006), the Hawaii Ovarian Cancer Study (HAWAII)
(Goodman et al, 2001b), the Hormones and Ovarian Cancer
Prediction Study (HOPE) (Pearce et al, 2008a), the Mayo Clinic
Ovarian Cancer Case–Control Study (MAYO) (Sellers et al, 2005),
the North Carolina Ovarian Cancer Study (NCOCS) (Berchuck
et al, 2004), the New England-based Case–Control Study (Terry
et al, 2005), the Ovarian Contraceptive and Reproductive
Experiences study (Holt et al, 2007), the Orange and San Diego
Counties, California (UCI) study and the USC/Los Angeles County
Case–Control Studies of Ovarian Cancer (USC) (Pearce et al,
2008b). There are data from three European studies: the Danish
Malignant Ovarian Cancer Study (MALOVA) (Auranen et al, 2005;
Song et al, 2006), the UK SEARCH Ovarian Cancer Study
(SEARCH) (Auranen et al, 2005; Song et al, 2006), and the UK
Ovarian Population Study (UKOPS) (Ramus et al, 2008). Finally,
data were contributed by three studies from Australia: the
Australian Cancer Study (ACS) (Merritt et al, 2008), the Australian
Ovarian Cancer Study (AOCS) (Merritt et al, 2008), and Survey of
Women’s Health (SWH) (Spurdle et al, 2000). ACS and AOCS were
combined for analysis purposes. Details of all but DOVE and UCI
have been published earlier.
All studies have Institutional Review Board/Human Ethics
Committee approval for the work presented. In addition, Duke
University and the University of Southern California have
Institutional Review Board approval as data coordinating centers.
SNP selection
At the inception of the OCAC and annually thereafter, members
have provided a list of SNPs genotyped in their study population.
By early 2007, there were 10 SNPs which had been genotyped by at
least three groups: rs4680 in COMT, rs4646903 and rs1048943 in
CYP1A1, rs1056836 in CYP1B1, rs2740574 in CYP3A4, rs743572
in CYP17, rs3020450 in ESR2, rs1805386 in LIG4, rs3218536 in
XRCC2 and rs861539 in XRCC3. Some of these data have earlier
been published by individual groups (Spurdle et al, 2000, 2002;
Goodman et al, 2001a,b; Garner et al, 2002; Terry et al, 2003;
Auranen et al, 2005; Sellers et al, 2005; Webb et al, 2005; Beesley
et al, 2007; Holt et al, 2007; Pearce et al, 2008b). The original data
on these 10 SNPs were then submitted to a central database for
combined analysis. SNPs that showed some evidence for associa-
tion in original data were also genotyped in additional OCAC
studies for replication purposes.
Genotyping and quality control
The original data had been genotyped using a variety of methods
described in the reports of these individual data (see Table 1 for
references). For the replication genotyping, the 50 nuclease
Taqman allelic discrimination assay (Taqman; Applied
Biosystems, Foster City, CA, USA) was used by DOVE, HAWAII,
HOPE, MALOVA, MAYO, SEARCH, UCI, UKOPS and USC using
centrally supplied probes. ACS and AOCS used the Sequenom iPlex
gold genotyping platform (Sequenom Inc., San Diego, CA, USA).
For all genotype data, genotype frequencies by ethnic group and
study in controls were tested for deviation from Hardy–Weinberg
equilibrium (HWE). For the replication genotyping effort, we
applied the OCAC quality control guidelines which stipulated
intermixing of cases and controls on genotyping plates, including
duplicate samples with no less than 98% concordance rate, overall
call rate by each study of 95% or greater and call rate for each plate
of at least 90%. In addition, consistency across labs was confirmed
by genotyping a common set of 95 DNAs (90 CEPH trios and five
duplicate samples; HAPMAPPT01 provided by Coriell, Camden, NJ,
USA) with the requirement of 498% concordance in genotype calls.
Data analysis
Each group provided age and race/ethnicity for all participants and
tumour histology for cases. Data analyses were restricted to
invasive epithelial ovarian cancers and included White, Black and
Latina individuals. Unconditional logistic regression stratified on
study, age (five groups: o40, 40–49, 50–59, 60–69, 70þ years),
and race/ethnicity, was used to analyze the data (SAS Version 9.1,
Cary, NC, USA). Each SNP was evaluated under three genetic
models: a co-dominant log additive model, a dominant model and
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Study (Ref)
a Location
Years
conducted Control ascertainment Case ascertainment
No. of controls/
cases SNPs genotyped
ACS Australia 2002–2005 Randomly selected from
Commonwealth electoral roll.
Frequency matched for age and
geographical region.
Cancer registries of New South Wales and
Victoria.
364/166 rs2740574 (CYP3A4), rs1805386 (LIG4)
AOCS (Beesley
et al, 2007)
Australia 2002–2006 Randomly selected from
Commonwealth electoral roll.
Frequency matched for age &
geographical region.
Recruited through surgical treatment
centres throughout Australia and cancer
registries of Queensland, South Australia
and West Australia.
698/558 rs2740574 CYP3A4), rs1805386 (LIG4),
rs3218536 (XRCC2), rs861539 (XRCC3)
DOVE Washington, USA 2002–2005 Random-digit dial identification
from study area. Frequency
matched to cases for race/ethnicity
and 5-year age group.
Cases diagnosed with primary invasive
ovarian cancer between 2002–2005 from
a 13-county area of western Washington
state.
744/548 rs3218536 (XRCC2)
GEOCS (Auranen
et al, 2005)
Northern
California, USA
1997–2002 Random-digit dial identification
from study area. Frequency
matched to cases for 5-year age
group and race/ethnicity.
Greater Bay Area Cancer Registry,
San Francisco.
419/317 rs1805386 (LIG4), rs3218536 (XRCC2),
rs861539 (XRCC3)
HAWAII
(Goodman et al,
2001a, b)
Hawaii, USA 1993 onwards Randomly selected from Hawaii
Department of Health Annual
Survey of the representatives
households.
Rapid case ascertainment through Hawaii
Tumour Registry.
160/70 rs4680 (COMT), rs4646903 (CYP1A1),
rs1048943 (CYP1A1), rs1056836
(CYP1B1), rs2740574 (CYP3A4), rs743572
(CYP17), rs3020450 (ESR2), rs3218536
(XRCC2)
HOPE NY, OH and PA,
USA
2003 onwards Identified in same regions.
Frequency matched for age and
ethnicity.
Physician offices, cancer registries and
pathology databases from counties of
western PA, eastern OH and western NY.
662/297 RS3218536 (XRCC2)
MALOVA
(Auranen et al,
2005)
Denmark 1994–1999 Random sample of general female
population (35–79 years of age) in
study area. Selected using
computerised Central Population
Register and matched to cases for
age and geographical region.
Incident cases (35–79 years of age) from
municipalities of Copenhagen and
Frederiksberg and surrounding counties.
1197/42 rs2740574 (CYP3A4), rs1805386 (LIG4),
rs3218536 (XRCC2), rs861539 (XRCC3)
MAYO (Sellers
et al, 2005)
Mayo Clinic, USA 2000 onwards Healthy women seeking general
medical examination identified
through Mayo Clinic. Frequency
matched to cases for age, race, and
state of residence.
Cases attending Mayo Clinic identified in a
six-state surrounding region.
442/325 rs4680 (COMT), rs1048943 (CYP1A1),
rs1056836 (CYP1B1), rs3218536 (XRCC2)
NCOCS North Carolina,
USA
1999 onwards Controls identified from same
region. Frequency matched to cases
for age and race.
Identified from 48 counties within the
region by rapid-case ascertainment.
941/702 rs2740574 (CYP3A4), rs743572 (CYP17),
rs3020450 (ESR2), rs1805386(LIG4),
rs3218536(XRCC2), rs861539 (XRCC3)
NECC (Garner
et al, 2002; Terry
et al, 2003)
New England,
USA
1992–2003 Controls identified through random
digit dialing, townbooks, and
drivers’ license lists. Frequency
matched to cases on age and state
of residence.
Identified through hospital tumour boards
and state cancer registries in New
Hampshire and Massachusetts.
484/268 rs4646903 (CYP1A1), rs1048943
(CYP1A1), rs743572 (CYP17), rs3020450
(ESR2)
OVCARE (Holt
et al, 2007)
Washington, USA 1994–1998 Controls identified through random
digit dialing in same three
geographic regions as cases.
Incident cases (35–54 years of age)
identified by SEER population-based cancer
registries serving metropolitan Atlanta,
Detroit, and Seattle areas.
577/188 rs4680 (COMT), rs4646903 (CYP1A1),
rs1048943 (CYP1A1), rs1056836
(CYP1B1)
SEARCH (Auranen
et al, 2005)
UK 1991 onwards Selected from the EPIC-Norfolk
cohort of 25,000 individuals aged
45–74, based in the same
geographical regions as cases.
Caeseo70 years from East Anglian, West
Midlands & Trent regions of England.
Prevalent cases diagnosed 1991–1998;
incident cases diagnosed 1998 onwards.
1221/851 rs1805386 (LIG4), rs3218536 (XRCC2),
rs861539 (XRCC3)
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sa recessive model. Results are given for the heterozygous
and homozygous risk estimates.
Information on a first-degree family history of ovarian cancer
was available on approximately 75% of cases and controls.
Stratified analyses were conducted on this subset of subjects.
The original and replication data were analyzed separately and
combined using the same methods. Heterogeneity across studies
was tested using the likelihood ratio test by fitting models with and
without interaction terms for study and SNP based on the final
model presented in the results.
Published data from non-OCAC members were available on
three SNPs: rs4680 (COMT) (Goodman et al, 2000), rs4646903
(CYP1A1, also known as CYP1A1 Msp1) (Sugawara et al, 2003)
and rs1048943 (CYP1A1, also known as CYP1A1*3) (Aktas et al,
2002; Sugawara et al, 2003). The odds ratios and 95% confidence
intervals from these published reports were abstracted and a meta-
analysis was conducted utilizing these data as well as the OCAC
data using Stata (Version 9, StataCorp, College Station, TX, USA).
Both random and fixed-effects models were evaluated.
RESULTS
Details of the 16 case–control studies that provided data for these
analyses are shown in Table 1. Genotype frequencies in White
controls were consistent with HWE for all SNPs/studies except
rs2740574 (CYP3A4) in HAW (P¼0.04) (Supplementary Table 1).
These data were retained in the analyses as the deviation was small,
the clustering was unambiguous and given the number of SNP/
study combinations evaluated it is likely to represent a chance
finding.
Seven of the 10 SNPs showed no evidence of an association
with invasive epithelial ovarian cancer (ovarian cancer;
Table 2). These SNPs were not further evaluated in the
OCAC, but three of them (COMT rs4680, CYP1A1 rs4646903,
and CYP1A1 1048943) had been studied by groups outside
of the OCAC and thus meta-analyses of the published
literature and OCAC data were conducted. Neither the COMT
variant nor the CYP1A1 rs4646903 variant were statistically
significantly associated with ovarian cancer risk on meta-analysis
(data not shown).
The CYP1A1 rs1048943 which showed a non-statistically
significant 10% increased risk of ovarian cancer per copy of the
minor allele carried in the OCAC dataset (95% CI 0.77–1.57) was
statistically significantly associated with risk of ovarian cancer on
meta-analysis with the published literature and the OCAC data
(ORadditive(add)¼1.81, 95% CI 1.36–2.40, Po0.001) under a fixed
effects model, but not a random-effects model (ORadd¼1.61, 95%
CI 0.74–3.51, P¼0.23). The meta-analysis also revealed significant
heterogeneity across studies (Po0.001).
Three SNPs showed evidence of an association with ovarian
cancer in the original OCAC data and were evaluated in additional
case–control studies from OCAC members (Table 3; Figure 1).
Based on original genotype data (three studies: 563 cases, 664
controls), CYP3A4 rs2740574 was associated with an increased risk
of invasive ovarian cancer among women who carried two copies
of the minor allele (P¼0.015). There was a 3.7-fold increased risk
associated with carrying two copies of the minor allele. Similar
results were found when this SNP was genotyped by three
additional OCAC sites in an additional 1406 cases and
2827 controls, but the confidence interval was wide
(ORhomozygous(hom)¼2.50, 95% CI 0.54–11.54, P¼0.24; Table 3)
because the follow-up data consisted of White individuals in which
the minor allele frequency was very low. In the combined dataset,
women carrying two copies of this allele had a 2.8-fold increased
risk of ovarian cancer (ORhom¼2.81, 95% CI 1.20–6.56,
phom¼0.017; Table 3; Figure 1). There was no evidence of
heterogeneity across study sites (phet¼0.42). This finding was
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sconsistent across histological subtypes (Table 4). There was no
evidence of statistical interaction with family history (P¼0.52).
The minor allele frequency for rs2740574 in White controls was
3.5%, compared with 59.7% in Blacks. The association between this
CYP3A4 variant and risk of ovarian cancer was consistent across
these two racial/ethnic groups in the combined existing and
follow-up data: ORhom in Blacks¼6.82 (95% CI 0.73–63.86,
P¼0.093) and ORhom in Whites¼2.40 (95% CI 0.67–8.68,
P¼0.18).
There was a 21% increased risk of ovarian cancer associated
with the rs1805386 variant in LIG4 among heterozygous carriers
and a 34% increased risk among homozygous carriers (P¼0.013
and P¼0.15, respectively; Table 3) in the original data. When this
SNP was genotyped by four additional OCAC sites (1691 cases and
2944 controls) a decreased risk of ovarian cancer was observed
(ORheterozygous (het)¼0.87, P¼0.046 and ORhom¼0.67, P¼0.056;
Table 3). After combining the original and replication data there
was no association between rs1805386 and risk of ovarian cancer
(ORhet¼0.97, P¼0.61, ORhom¼0.68, P¼0.11; Table 3; Figure 1)
in 3321 cases and 5140 controls. There was a significant
heterogeneity across the study sites (P¼0.001); the heterogeneity
was not attributable to any single study. There was no evidence of
statistical interaction with family history (P¼0.50).
We found borderline evidence of a decrease in ovarian cancer
risk associated with the XRCC2 variant rs3218536 using a log-
additive model in the original data provided by six OCAC sites
(OR¼0.89, 95% CI 0.78–1.02, P¼0.095) with 2763 cases and 5479
controls. This SNP was genotyped by seven additional OCAC sites
comprising 2551 cases and 4005 controls and no association was
observed with ovarian cancer risk (Table 3). In the combined data
there was no association between rs3218536 and risk of ovarian
cancer (Table 3; Figure 1). There was neither any evidence of
heterogeneity across study sites (P¼0.30), nor histological
subtype-specific effects. There was also no evidence of statistical
interaction with family history (P¼0.25).
DISCUSSION
We evaluated the association between 10 SNPs from nine genes
and ovarian cancer risk using existing data from 16 studies that
participate in the OCAC. We found borderline evidence for
association with ovarian cancer risk for three of these variants and
replication genotyping was carried out to provide more definitive
evidence of association. In the combined data, only rs2740574 in
CYP3A4 was associated with disease among women who carried
two copies of the minor allele (P¼0.017). This finding was
consistent across the original and replication data and also across
White and Black racial/ethnic groups and histological subtypes
(Table 4).
CYP3A4 encodes an enzyme critical for oxidation of oestrogens
(Keshava et al, 2004) and its inhibition results in higher circulating
oestrogen levels (Monroe et al, 2007). Given that exposure to
oestrogen is associated with the risk of ovarian cancer (Beral et al,
2007) it is plausible that the CYP3A4 rs2740574 variant might
influence ovarian cancer development through decreased expres-
sion of the gene and thus reduced metabolism of oestrogen. In
addition to hormone metabolism, CYP3A4 is also involved in the
Table 2 Summary odds ratio (per allele) and 95% confidence interval for risk of invasive epithelial ovarian cancer among the indicated OCAC studies for
SNPs that showed no association with ovarian cancer
Gene SNP
Controls
(N)
Cases
(N)
ORhet
a
(95% CI) P-value
ORhom
a
(95% CI) P-value Studies
COMT rs4680 874 381 1.01 (0.75–1.36) 0.96 1.00 (071–1.42) 0.98 HAWAII, MAYO OVCARE
CYP1A1 rs4646903 1182 490 1.15 (0.89–1.50) 0.29 0.77 (0.28–2.13) 0.61 HAWAII, NECC, OVCARE
CYP1A1 rs1048943 1308 611 1.13 (0.79–1.63) 0.50 — 0.97 HAWAII, MAYO, NECC, OVCARE
CYP1B1 rs1056836 875 384 0.91 (0.69–1.21) 0.52 0.83 (0.58–1.19) 0.31 HAWAII, MAYO OVCARE
CYP17 rs743572 1594 1078 1.09 (0.91–1.30) 0.36 1.19 (0.93–1.52) 0.17 HAWAII, NCOCS, NECC, SWH, USC
ESR2 rs3020450 2198 1523 0.95 (0.83–1.10) 0.52 1.09 (0.87–1.36) 0.44 HAWAII, NCOCS, NECC, USC
XRCC3 rs861539 5186 2352 0.92 (0.82–1.04) 0.17 1.01 (0.85–1.19) 0.95 AOCS, MALOVA, NCOCS, SEARCH, GEOCS, SWH
aCI¼confidence interval; het¼heterozygous carriers; hom¼homozygous carriers; OR¼odds ratio. All ORs stratified on study site, race/ethnicity and age.
Table 3 Summary odds ratio and 95% confidence interval for risk of invasive epithelial ovarian cancer among OCAC studies for the three SNPs associated
with risk of ovarian cancer in original data
95% CI P-value
Controls (N) Cases (N)O R het
a CYP3A4 rs2740574
b ORhom
a 95% CI P-value
Original data 664 563 1.51 0.85–2.40 0.084 3.66 1.29–10.40 0.015
Replication data 2827 1406 0.96 0.73–1.25 0.75 2.50 0.54–11.54 0.24
Combined data 3491 1969 1.07 0.85–1.34 0.57 2.81 1.20–6.56 0.017
LIG4 rs1805386
c
Original data 2196 1630 1.21 1.04–1.40 0.013 1.34 0.90–1.99 0.15
Replication data 2944 1691 0.87 0.75–1.00 0.046 0.67 0.45–1.01 0.056
Combined data 5140 3321 1.01 0.91–1.12 0.82 0.94 0.71–1.25 0.68
XRCC2 rs3218536
d
Original data 3668 2763 0.92 0.79–1.06 0.24 0.60 0.31–1.17 0.13
Replication data 4005 2551 1.05 0.91–1.21 0.50 0.79 0.40–1.57 0.50
Combined data 7673 5314 0.97 0.88–1.08 0.61 0.68 0.42–1.09 0.11
ahet¼heterozygous carriers; OR¼odds ratio; hom¼homozygous carriers.
bStudies included in original data: HAWAII, NCOCS, SWH; studies included in follow-up data: ACS,
AOCS, MALOVA, UKOPS.
cStudies included in original data: GEOCS, NCOCS, SEARCH; studies included in follow-up data: ACS, AOCS, MALOVA, USC.
dStudies included in
original data: AOCS, GEOCS, MALOVA, NCOCS, SEARCH, SWH; studies included in follow-up data DOVE, HAWAII, HOPE, MAYO, SEARCH (additional accrued cases),
UCI, UKOPS, USC.
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smetabolism of approximately half of all marketed drugs, therefore
individuals with differences in CYP3A4 expression might have
different responses to any number of exogenous compounds,
including oral contraceptives, an ovarian cancer protective factor.
The rs2740574 SNP is in the promoter region of the gene, but
efforts to show a functional effect of this variant have proved difficult.
Spurdle et al (2002) evaluated multiple reporter gene constructs, but
found no differences in the transcription between the putative disease
and wild-type allele; the results of other functional studies have been
equivocal (Ball et al, 1999; Westlind et al, 1999; Amirimani et al, 2003;
Rodriguez-Antona et al, 2005). Alternatively, it may be that rs2740574
is simply in linkage disequilibrium with the causal variant, which
remains to be identified. Using data from the International Haplotype
Map Project (HapMap) to examine the region that includes CYP3A4,
CYP3A5 and CYP3A7 genes and the 20kb flanking this region, there
are six variants in perfect linkage disequilibrium with rs2740574. Five
of these variants are in the region immediately 50 of CYP3A4 and one
is in intron 2 of the gene. Any of these SNPs, or an unidentified
variant in linkage disequilibrium, could be the causal allele. At
present, there are no data to support a functional role for any of these
variants in ovarian cancer development. Additional follow-up is
warranted to confirm the association between this CYP3A4 variant
and risk of ovarian cancer, and ideally these studies should be
performed in different racial groups.
Two additional variants, one in LIG4 and the other in XRCC2,
evaluated as part of this project, showed association in the original
0.1 1 10 0.1 10 11 0 0
A
Relative risk–heterozygous carriers  Relative risk–homozygous carriers 
ACS/AOCS
HAWAII
MALOVA
NCOCS
SWH
UKOPS
Combined
0.1 1 10 0.1 1 10
B
Relative risk–heterozygous carriers  Relative risk–homozygous carriers 
ACS/AOCS
GEOCS
MALOVA
NCOCS
SEARCH
USC
Combined
0.1 1 10 0.01 0.1 10 1 100
AOCS
DOVE
GEOCS
HAWAII
HOPE
MALOVA
MAYO
NCOCS
SEARCH
SWH
UCI
UKOPS
USC
Combined
Relative risk–heterozygous carriers  Relative risk–homozygous carriers 
C
Figure 1 Forest plots of the study-specific and summary-relative risk and 95% confidence intervals for the association between ovarian cancer risk and
three SNPs in the CYP3A4, LIG4 and XRCC2 genes. (A) rs2740574 in CYP3A4. The overall summary ovarian cancer risk among heterozygous carriers is
1.07 (0.85–1.34, P¼0.57) and homozygous carriers is 2.81 (95% CI 1.20–6.56, P¼0.017). (B) rs1805386 in LIG4. The overall summary ovarian cancer
relative risk among heterozygous carriers is 1.01 (95% CI 0.91–1.12, P¼0.82) and homozygous carriers is 0.94 (95% CI 0.71–1.25, P¼0.68).
(C) rs3218536 in XRCC2. The overall summary ovarian cancer relative risk among heterozygous carriers is 0.97 (95% CI 0.88–1.08, P¼0.61) and
homozygous carriers 0.68 (95% CI 0.42–1.09, P¼0.11).
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sdata provided by OCAC sites, but no association was observed
after replication genotyping was carried out in additional OCAC
studies. The LIG4 variant, rs1805386, showed significant hetero-
geneity across studies (P¼0.001) for reasons that could not be
elucidated. It is perplexing that the original data suggested a
statistically significant positive association with risk, whereas the
replication data suggested an inverse relationship. In the absence
of any reasonable explanation it is likely that the heterogeneity was
due to chance. The failure to replicate the association with the
XRCC2 variant rs3218536 was not surprising as the evidence of
association in the original data was weak under a co-dominant
genetic model (P¼0.095).
Seven additional variants did not show an association with the
risk of ovarian cancer in the OCAC dataset. Three of these variants
have been studied by groups outside the OCAC: rs4680 (COMT)
(Goodman et al, 2000), rs4646903 (CYP1A1, also known as
CYP1A1 Msp1) (Sugawara et al, 2003) and rs1048943 (CYP1A1,
also known as CYP1A1*3) (Aktas et al, 2002; Sugawara et al, 2003).
Neither the COMT variant nor the CYP1A1 rs4646903 variant were
associated with the risk of ovarian cancer on meta-analyses of the
published literature and the OCAC data.
The CYP1A1 rs1048943 variant was associated with a non-
statistically significant increased risk of ovarian cancer per copy of
the minor allele carried in the OCAC dataset and in a Japanese
population (ORadd¼1.16, 95% CI 0.44-3.05) (Sugawara et al,
2003); in a Turkish population it was associated with a statistically
significant increased risk of ovarian cancer (ORadd¼6.20, 95% CI
3.62–10.46) (Aktas et al, 2002). Overall, the meta-analysis of the
published literature and the OCAC data showed a statistically
significant increased risk of ovarian cancer (ORadd¼1.81, 95% CI
1.36–2.40, Po0.001) under a fixed-effects model, but not a
random-effects model (ORadd¼1.61, 95% CI 0.74–3.51, P¼0.23).
The meta-analysis also revealed significant heterogeneity across
studies (Po0.001) bringing this association into question. Further
follow-up of this variant may be warranted.
There are several limitations to this study. The association with
CYP3A4 rs2740574 was consistent in the original and replication
data and was consistent across racial/ethnic groups, but it was
restricted to homozygous carriers of the minor allele. The risk
allele is rare in Whites and the result is based on few cases and
while the SNP is common in Blacks there are few included in this
study. Also, four of the SNPs (rs4646903 and rs1048943 in CYP1A1,
rs1056836 in CYP1B1, and rs743572 in CYP17), which were not
statistically significantly associated with ovarian cancer and
therefore not followed up by the OCAC, were associated with
B10% increased or decreased risk of ovarian cancer per copy of
the allele carried. This size of effect is of the same magnitude as
those observed in a recent breast cancer genome-wide association
scan (Easton et al, 2007). Some of these results could be false
negatives as we were only powered to detect odds ratios of B1.18
and higher for these SNPs with 80% power and an a of 0.05. We
also observed significant heterogeneity with the SNP in LIG4,
which may have been a chance finding, but may have resulted from
underlying differences in the study populations, an issue with
pooled-analyses.
In conclusion, we have identified a possible association between
an SNP (rs2740574) in the key oestrogen-metabolizing gene
CYP3A4 and ovarian cancer risk. Follow-up of this association is
warranted, especially in Blacks. Our study also underscores the
importance of consortium-based replication of genetic epidemio-
logical studies to achieve large sample sizes.
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